On January 31, 2024, L. Mary Smith, the Company?s Chief Development Officer, notified SpringWorks Therapeutics, Inc. (the ?Company?) that she will be resigning due to the demands of her caretaker role in connection with a family member?s illness, effective January 31, 2024 (the ?Effective Date?). Dr. Smith?s resignation as Chief Development Officer of the Company is not the result of any dispute or disagreement with the Company or the Board, or any matter relating to the Company?s operations, policies or practices. In connection with her resignation, Dr. Smith and the Company entered into a Separation and Consulting Agreement (the ?Separation and Consulting Agreement?) pursuant to which Dr. Smith will act as Senior Strategic Advisor to the Company, effective as of the day immediately following the Effective Date.